Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Public ClinicalTrials.gov record NCT00782301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B
Study identification
- NCT ID
- NCT00782301
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- ViiV Healthcare
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- etravirine Drug
- maraviroc Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Jan 31, 2010
- Completion
- Jan 31, 2010
- Last update posted
- Jan 18, 2012
2009 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Clearwater | Florida | 33765 | — |
| Pfizer Investigational Site | Orlando | Florida | 32803 | — |
| Pfizer Investigational Site | Safety Harbor | Florida | 34695 | — |
| Pfizer Investigational Site | Wilton Manors | Florida | 33305 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30308 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30312 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01605 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01655 | — |
| Pfizer Investigational Site | Mount Vernon | New York | 10550 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74135 | — |
| Pfizer Investigational Site | Bellaire | Texas | 77401 | — |
| Pfizer Investigational Site | Conroe | Texas | 77301 | — |
| Pfizer Investigational Site | Dallas | Texas | 75390 | — |
| Pfizer Investigational Site | Stafford | Texas | 77477 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00782301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2012 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00782301 live on ClinicalTrials.gov.